Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TeGenero Incident Victims
May 15, 2006
- Banyu to Focus on Basic Research,
May 15, 2006
- R&D NEWS IN BRIEF
May 15, 2006
- New Drug Improves Quality of Sleep: Rohto
May 15, 2006
- Abbott Acquires Guidant Vascular Business
May 15, 2006
- Astellas Licenses Anemia
May 15, 2006
- Morimoto-Iyaku Establishes
May 15, 2006
- Novartis Pharma Integrates Marketing Systems
May 15, 2006
- MEDICAL DEVICE NEWS IN BRIEF
May 15, 2006
- BUSINESS NEWS IN BRIEF
May 15, 2006
- ANNUAL BUSINESS RESULTS
May 15, 2006
- ANNUAL BUSINESS RESULTS
May 15, 2006
- Opinions Heard from
May 15, 2006
- Torii: Transfer of TachoComb Drives Down Sales
May 15, 2006
- JMA Reluctantly Accepts Healthcare Reform Bill
May 15, 2006
- Schering-Plough's Temodar
May 15, 2006
- 15% of Prescriptions Allow
May 15, 2006
- RDKK Supports Nursery for Female Doctors with Children
May 8, 2006
- JT Licenses New Drug Candidate to GSK
May 8, 2006
- SELF-MEDICATION NEWS IN BRIEF
May 8, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…